Ondansetron

Type: Product
Name: Ondansetron
First reported Jul 10 2014 - Updated Jul 10 2014 - 1 reports

ONDANSETRON Tablet, Orally Disintegrating [Cardinal Health]

First reported Jul 04 2014 - Updated Jul 04 2014 - 1 reports

Aprepitant Prevents CINV in Young Cancer Patients Also

Aprepitant ( Emend , Merck & Co.), which is already approved for use in adults for the prevention of chemotherapy-induced nausea and vomiting (CINV), has now been shown to also be effective in children and adolescents (ranging from 6 months to 17 yea ... [Published American Journal of Public Health - Jul 04 2014]
First reported Jun 30 2014 - Updated Jun 30 2014 - 1 reports

Emend Eases Children’s Chemotherapy-Induced Nausea and Vomiting, Study Shows

Merck plans FDA submission in second half of 2014The addition of Emend (aprepitant, Merck) to a standard treatment regimen significantly reduced chemotherapy-induced nausea and vomiting (CINV) in pediatric cancer patients in a large phase III trial.The ... [Published P&T Community - Jun 30 2014]
First reported Jun 30 2014 - Updated Jun 30 2014 - 1 reports

When side effects can be used to help patients

While over-medication is harmful, the adverse effects of drugs can be turned to therapeutic advantage The suspicion that over-medication with preventive drugs may shorten, rather than prolong, life was strikingly confirmed in a recent study of nearly ... [Published Telegraph - Jun 30 2014]
First reported Jun 29 2014 - Updated Jun 29 2014 - 1 reports

Aprepitant Yields Significant Benefits for the Prevention of CINV in Children

Peter J. Sciavolino, PhDIn the first large pediatric study of adding the NK-1 receptor antagonist aprepitant to standard prophylaxis for chemotherapy-induced nausea and vomiting (CINV), researchers have found aprepitant to be significantly more effective ... [Published OncLive - Jun 29 2014]
First reported Jun 26 2014 - Updated Jun 26 2014 - 1 reports

Morning sickness drug linked to birth defects: Report

Photo: iStockphotoYesterday, the  Toronto Star  reported that an unapproved anti-nausea drug used for morning sickness is linked to birth defects. The drug—ondansetron—is being prescribed by doctors for Hyperemesis gravidarum (the kind of extreme morning ... [Published Today's Parent - Jun 26 2014]
First reported Jun 25 2014 - Updated Jun 26 2014 - 1 reports

Birth defects blamed on unapproved morning sickness treatment

Canadian women with severe morning sickness are being prescribed a powerful anti-nausea drug suspected of causing deformities in some babies, a Toronto Star investigation has found.The drug, ondansetron, is approved by Health Canada to treat nausea and ... [Published Toronto Star Online - Jun 25 2014]
First reported Jun 10 2014 - Updated Jun 10 2014 - 1 reports

FDA Approves Palonosetron Hydrochloride for Prevention of  Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients

By The ASCO PostJune 10, 2014, Volume 5, Issue 9Figures:The U.S. Food and Drug Administration (FDA) has approved palonosetron hydrochloride (Aloxi) injection for the prevention of acute nausea and vomiting associated with initial and repeat courses of ... [Published The ASCO Post - Jun 10 2014]
First reported Jun 02 2014 - Updated Jun 02 2014 - 2 reports

ONDANSETRON Tablet, Orally Disintegrating [Sandoz Inc]

Entities: Ondansetron, Sandoz
First reported May 29 2014 - Updated May 30 2014 - 2 reports

ONDANSETRON Tablet, Film Coated [Sandoz Inc]

Entities: Ondansetron, Sandoz
First reported May 22 2014 - Updated May 22 2014 - 1 reports

ONDANSETRON (Ondansetron Hydrochloride) Solution [NorthStar Rx LLC]

First reported May 12 2014 - Updated May 13 2014 - 1 reports

ONDANSETRON Tablet, Orally Disintegrating [Proficient Rx]

Entities: Ondansetron

Quotes

Dror Ben-Asher, RedHill's CEO, said: "The acquisition of MESUPRON® reflects our commitment to patients suffering from gastrointestinal and inflammatory diseases, including related cancers such as pancreatic cancer, gastric cancer and colorectal cancer. It adds to RedHill's pipeline of six late clinical-stage drug candidates and fits well with our risk-mitigating business model. MESUPRON® is a unique non-cytotoxic approach targeting oncology indications where there is a very strong demand for better therapeutic options. Thanks to the development work conducted by WILEX, MESUPRON® is supported by extensive pre-clinical and clinical data, and we believe in its potential to become an important treatment option for cancer patients. Our experienced development team is enthusiastic to advance this important new drug. We look forward to collaborating with our new partner WILEX and would like to thank them for entrusting us with the development and commercialization of MESUPRON®."
...She started as a sceptic, but before long, "I could feel the hinges of my brain, almost literally, creaking apart to make room for new ideas" . The gentleman, as featured last week, with severe bladder pain for an hour after (but never while) passing urine has prompted several further reports...
...particular brain cells become overactive in response to the very large increases in hormone levels that occur early in pregnancy," Guttuso says.  "We theorize that this overactivity is partially mediated by too much calcium inflow and that leads to the symptoms of nausea and vomiting.  Gabapentin most likely works by preventing the flow of calcium ions into particular brain cells that are involved with the generation of nausea and vomiting."
..."Never underestimate the power of 20 minutes outside your house, taking deep breaths," she said. "Walking increases serotonin levels in the brain and makes women feel better. This increases their coping ability."

More Content

All (59) | News (28) | Reports (0) | Blogs (27) | Audio/Video (0) | Fact Sheets (1) | Press Releases (3)
sort by: Date | Relevance
RedHill Biopharma (PINK:REDIF) Acquires Phase I... [Published Live Trading News - 8 hours ago]
ONDANSETRON Tablet, Film Coated [Bryant Ranch P... [Published DailyMed Drug Label Updates for the last seven ... - Jul 11 2014]
ONDANSETRON Tablet, Film Coated [Bryant Ranch P... [Published DailyMed Drug Label Updates for the last seven ... - Jul 11 2014]
ONDANSETRON Tablet, Orally Disintegrating [Card... [Published DailyMed Drug Label Updates for the last seven ... - Jul 10 2014]
The problem with off-label drugs [Published Toronto Star Online - Jul 05 2014]
Aprepitant Prevents CINV in Young Cancer Patien... [Published American Journal of Public Health - Jul 04 2014]
RedHill Acquires Mesupron from Wilex [Published Yahoo! Finance - Jul 03 2014]
Gastroparesis [Published Today's Dietitian - Jul 03 2014]
Emend Eases Children’s Chemotherapy-Induced Nau... [Published P&T Community - Jun 30 2014]
RedHill Biopharma Acquires Phase II Oncology Dr... [Published GlobeNewswire - Jun 30 2014]
When side effects can be used to help patients [Published Telegraph - Jun 30 2014]
Aprepitant Yields Significant Benefits for the ... [Published OncLive - Jun 29 2014]
Morning sickness drug linked to birth defects: ... [Published Today's Parent - Jun 26 2014]
RedHill Biopharma Announces Positive Preliminar... [Published Market Pulse Navigator - Jun 26 2014]
Dangers of off-label drug use kept secret [Published Toronto Star Online - Jun 26 2014]
Birth defects blamed on unapproved morning sick... [Published Toronto Star Online - Jun 25 2014]
Tender for the delivery of cytostatics, adjuvan... [Published Pharmacy Choice - Jun 20 2014]
Drug Combating Severe Nausea in Pregnancy Begin... [Published HealthNewsDigest.com - Jun 18 2014]
Forum Post: RE: Any advice on dosetaxel please [Published Macmillan Cancer Support - Jun 14 2014]
Malignant Hyperthermia: Is Your Institution Pre... [Published Michigan Pharmacists Association - Jun 13 2014]
RedHill Biopharma to Present at the Wells Fargo... [Published BusinessWeek - Jun 11 2014]
FDA Approves Palonosetron Hydrochloride for Pre... [Published The ASCO Post - Jun 10 2014]
Managing Nausea in Pregnancy [Published Advance for NPs and PAs - Jun 10 2014]
RedHill Biopharma Announces New RHB-104 Patent ... [Published GlobeNewswire - Jun 05 2014]
ONDANSETRON Tablet, Film Coated [Proficient Rx LP] [Published DailyMed Drug Label Updates for the last seven ... - Jun 04 2014]
FDA Approves ALOXI® palonosetron HCl to Prevent... [Published 4 Traders - Jun 04 2014]
ONDANSETRON Tablet, Film Coated [Sandoz Inc] [Published DailyMed Drug Label Updates for the last seven ... - Jun 02 2014]
ONDANSETRON Tablet, Film Coated [Cardinal Health] [Published DailyMed Drug Label Updates for the last seven ... - Jun 02 2014]
ONDANSETRON Tablet, Orally Disintegrating [Sand... [Published DailyMed Drug Label Updates for the last seven ... - Jun 02 2014]
ONDANSETRON Tablet, Orally Disintegrating [St M... [Published DailyMed Drug Label Updates for the last seven ... - Jun 02 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
ONDANSETRON Tablet, Film Coated [Bryant Ranch P... [Published DailyMed Drug Label Updates for the last seven ... - Jul 11 2014]
Updated Date: Jul 11, 2014 EST ...
ONDANSETRON Tablet, Film Coated [Bryant Ranch P... [Published DailyMed Drug Label Updates for the last seven ... - Jul 11 2014]
Updated Date: Jul 11, 2014 EST ...
ONDANSETRON Tablet, Orally Disintegrating [Card... [Published DailyMed Drug Label Updates for the last seven ... - Jul 10 2014]
Updated Date: Jul 10, 2014 EST ...
ONDANSETRON Tablet, Film Coated [Proficient Rx LP] [Published DailyMed Drug Label Updates for the last seven ... - Jun 04 2014]
Updated Date: Jun 4, 2014 EST ...
ONDANSETRON Tablet, Film Coated [Sandoz Inc] [Published DailyMed Drug Label Updates for the last seven ... - Jun 02 2014]
Updated Date: May 30, 2014 EST ...
1 2 3 4 5 6

Press Releases

sort by: Date | Relevance
RedHill Biopharma Reports Successful RHB-102 Bi... [Published GlobeNewswire: Advertising News - Apr 30 2014]
RedHill Biopharma Announces Positive European S... [Published GlobeNewswire: Advertising News - Apr 07 2014]
RedHill Biopharma Provides Update on RHB-102 De... [Published GlobeNewswire: Acquisitions News - Mar 07 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.